🔗15thasgo.com Congratulations on ASGO’s 15th anniversary🎉 This year marks the 15th anniversary of the ASGO.

Do you address REGION 2️⃣ routinely in advanced ovarian cancer? The superior recess of the lesser sac is a 'hidden region' where disease could be missed if not looked 👀 for Acc to the results of this study, exploration of this region should be performed in all pts with

To Korean members: Join our #ChemoTIP workshop on Jan 13. The program covers vital aspects from #chemotherapy basics to #TargetedTherapy, and managing their #AdverseEvents – it's a comprehensive dive into practical issues, including #insurance policies.

Happy new year:) ASGO Summary for endometrial cancer 2023 is now online! KSGO 🔗asgoed.org/html/?pmode=BB…

✔️Online first article: 🇰🇷 KSGO developed updated guidelines for treatments of EOC 🔑Key items: PARP inhibitors, 2nd CRS, bevacizumab 🔗 ejgo.org/DOIx.php?id=10…

✔️From the large population-based cohort (1,582 patients from Netherlands Cancer Registry), KELIM was prognostic for radiological response and the likelihood of complete IDS after NACT (OR=2.59), and prognostic for PFS(HR=0.76) and OS(HR=0.79) 🔗ejgo.org/DOIx.php?id=10…

After SHAPE trial, how will you treat low-risk cervical cancer? Check the JGO expert opinion: 🖇️Simple hysterectomy SHAPE-ing up to be the treatment of choice for early cervical cancer under 2 cm by Anouk Benseler and Allan Covens ejgo.org/DOIx.php?id=10…

🖍️After SHAPE, how will you treat low-risk cervical cancer? Check the JGO expert opinion: 🖇️ Is it time to change surgery for early-stage low-risk cervical cancer to simple hysterectomy? by Jeong-Yeol Park ejgo.org/DOIx.php?id=10…

#KSGO2024 is coming! Pre-registration is until April 14 📆 Hope to see you in #Busan

JGO editors met in KSGO! See you all next time 🌊🌊💙 KSGO

#TORPEDO- early outcomes in Journal of Gynecologic Oncology PFS (primary end-pt) data are now mature- will be presented later this year 🤞 ✅Primary end-pt achieved !! What's next? Multi-centre, multi-region validation 🔪 variations +path data 🚫NOT FOR ROUTINE CARE YET ejgo.org/DOIx.php?id=10…

Our new paper (regarding EPM2AIP1) is just out !! Unveiling pembrolizumab effectiveness in diverse subtypes of MSI-high endometrial cancers DOI: 10.3802/jgo.2024.35.e103 ejgo.org/DOIx.php?id=10… Journal of Gynecologic Oncology

🌟 Honoring Excellence! 🌟 At #KSGO2024, we awarded honorary memberships to Drs. Takayuki Enomoto & Mikio Mikami during our Presidential Dinner. Their dedication to #GynecologicOncology inspires us all. Congratulations to these trailblazers! 🏅

🚨 1st ASGO&ESGO joint webinar 1) ESGO new guideline for the AYA GYN cancer patients 2) Impact of Fertility Preservation on Ovarian Cancer : Clinical Analysis and Current Understandings in Asia Date and time June 20, 2024 (Thursday) at 19:00 KST 🔗 us06web.zoom.us/meeting/regist…

🫧 Cadavar workshop with Prof. Hiroyuki Kanao learning radical hysterectomy

Our new paper is just out!! HER2-negative or low expression as an unfavorable prognostic factor in patients with stage I/II uterine carcinosarcoma ejgo.org/DOIx.php?id=10… Journal of Gynecologic Oncology

✅Protocol for ROSELLA 🌹: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer 🔗URL: doi.org/10.3802/jgo.20…

🚨Editor's choice for July 2024 Journal of Gynecologic Oncology 📷A group that underwent lymphadenectomy had a survival advantage in serous histology compared to the group without lymphadenectomy. link: doi.org/10.3802/jgo.20…

🎙️Discover the JGO (Journal of Gynecologic Oncology) #Podcast, where we bring you the latest #research and breakthroughs in #GynecologicOncology. Search for "JGO" on #Spotify or #ApplePodcast!🎧 Journal of Gynecologic Oncology

🚨Editor's choice Phase II study of Niraparib in Japanese patients with heavily pretreated, HRD ovarian cancer: 20 patients were enrolled Confirmed ORR was 60.0% ejgo.org/DOIx.php?id=10…